Efficacy and safety of Azelnidipine-Telmisartan vs. Amlodipine-Telmisartan: a prospective randomized trial in Indian hypertensive patients.

OBJECTIVE

The present study aimed to assess the efficacy and safety of a fixed-dose combination (FDC) of Azelnidipine 16 mg and Telmisartan 40 mg compared to FDC of Amlodipine 5 mg and Telmisartan 40 mg in Indian essential hypertensive patients with a special focus on the impact on micro-albuminuria.

METHODS

This prospective, randomized, open-label 12-week study enrolled 225 patients with treatment-naive stage II hypertensive patients or hypertensive patients not controlled on Telmisartan 40 mg monotherapy. The eligible participants were randomized to receive either FDC of Azelnidipine-Telmisartan (Test group; n=115) or FDC of Amlodipine-Telmisartan (Reference group; n=110). Efficacy was assessed via changes in systolic and diastolic blood pressure (SBP/DBP), pulse rate (PR), and urinary albumin-to-creatinine ratio (UACR), a marker of microalbuminuria. Safety parameters were evaluated by documenting the adverse effects.

RESULTS

Both groups showed significant reductions in SBP and DBP from baseline, with no statistical difference among the groups. However, the test group expressed a more favorable effect on pulse rate, displaying a significant reduction compared to the reference group. Additionally, the occurrence of pedal edema was significantly lower in the test group vs. the reference group (1.7% vs. 9.1%). Changes in UACR were nominal and comparable in both groups, indicating limited renoprotective effects.

CONCLUSION

Collectively, the study confirms that FDC of Azelnidipine-Telmisartan is as effective as the commonly used FDC of Amlodipine-Telmisartan combination for management of hypertension, with additional safety benefits related to heart rate and edema. These findings support the clinical utility of Azelnidipine in hypertensive patients with concerns associated with tachycardia or pedal edema.